Alnylam Pharmaceuticals in Cambridge, UK seeks an imaginative physician drug developer to lead RNAi programs across neurology and hematology. The Director, Clinical Research, will drive the plasminogen program from Phase 2 to Phase 3, providing clinical leadership and oversight to global regulatory strategies.
You will report to the program strategy lead, supervise trial conduct and safety, and engage with external experts at regulatory and scientific meetings.
#J-18808-Ljbffr
Director, Clinical Research — RNAi Therapeutics Lead (Phase 2–3) in Cambridge employer: Alnylampharmaceuticals
Alnylam Pharmaceuticals is an exceptional employer, offering a dynamic work environment in the heart of the biotech industry. With a strong commitment to employee growth and a culture that values innovation and collaboration, team members are empowered to make meaningful contributions to cutting-edge CNS programs. The company's focus on regulatory excellence and adherence to core values ensures that employees are not only supported in their professional development but also engaged in impactful work that drives advancements in healthcare.
